Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.

× No keyword cloud information.

23 in total

1. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.

Authors: J Laliberté; V E Marquez; R L Momparler
Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333

Review 2. Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.

Authors: J L Grem; D D Shoemaker; D F Hoth; S A King; J Plowman; D Zaharko; C K Grieshaber; S D Harrison; J C Cradock; B Leyland-Jones
Journal: Invest New Drugs Date: 1987-12 Impact factor: 3.850

Review 3. Anticancer drug pharmacodynamics.

Authors: G Powis
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

4. The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia.

Authors: A L Harris; D G Grahame-Smith
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

5. Evaluation of in vitro predictive assays for acute myelocytic leukemia.

Authors: H D Preisler
Journal: Blut Date: 1980-11

6. Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.

Authors: A L Harris; C Potter; C Bunch; J Boutagy; D J Harvey; D G Grahame-Smith
Journal: Br J Clin Pharmacol Date: 1979-09 Impact factor: 4.335

7. Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.

Authors: J A Streifel; S B Howell
Journal: Proc Natl Acad Sci U S A Date: 1981-08 Impact factor: 11.205

8. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Authors: Jan H Beumer; Julie L Eiseman; Robert A Parise; Jeffry A Florian; Erin Joseph; David Z D'Argenio; Robert S Parker; Brittany Kay; Joseph M Covey; Merrill J Egorin
Journal: Cancer Chemother Pharmacol Date: 2007-11-15 Impact factor: 3.333

9. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.

Authors: H D Preisler; Y M Rustum; N Azarnia; R Priore
Journal: Cancer Chemother Pharmacol Date: 1987 Impact factor: 3.333

Review 10. Genetic factors influencing cytarabine therapy.

Authors: Jatinder K Lamba
Journal: Pharmacogenomics Date: 2009-10 Impact factor: 2.533